Nuo Therapeutics Inc
Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. It serves hospita… Read more
Nuo Therapeutics Inc (AURX) - Net Assets
Latest net assets as of June 2025: $-824.56K USD
Based on the latest financial reports, Nuo Therapeutics Inc (AURX) has net assets worth $-824.56K USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.36 Million) and total liabilities ($2.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-824.56K |
| % of Total Assets | -60.65% |
| Annual Growth Rate | -28.85% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 106.02 |
Nuo Therapeutics Inc - Net Assets Trend (2014–2024)
This chart illustrates how Nuo Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nuo Therapeutics Inc (2014–2024)
The table below shows the annual net assets of Nuo Therapeutics Inc from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $513.71K | -50.56% |
| 2023-12-31 | $1.04 Million | -52.58% |
| 2022-12-31 | $2.19 Million | +519.37% |
| 2021-12-31 | $-522.54K | -1.31% |
| 2020-12-31 | $-515.79K | -1.29% |
| 2019-12-31 | $-509.24K | -521.12% |
| 2018-12-31 | $-81.99K | -116.98% |
| 2017-12-31 | $482.87K | -96.13% |
| 2016-12-31 | $12.49 Million | +134.15% |
| 2015-12-31 | $-36.56 Million | -336.35% |
| 2014-12-31 | $15.47 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nuo Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7785190200.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $32.77 Million | 6379.77% |
| Total Equity | $513.71K | 100.00% |
Nuo Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Nuo Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
I GRANDI VIAGGI
F:95H
|
$30.40 Million |
|
Bioptik Technology
TWO:4161
|
$30.42 Million |
|
Bohae Brewery
KO:000890
|
$30.42 Million |
|
Elixir Energy Limited
PINK:ELXPF
|
$30.43 Million |
|
Premium Catering (Holdings) Limited
NASDAQ:PC
|
$30.39 Million |
|
SEOWONINTECH.Co.Ltd
KQ:093920
|
$30.39 Million |
|
WIZIT Co. Ltd
KQ:036090
|
$30.38 Million |
|
Pacific Valley Bank
PINK:PVBK
|
$30.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nuo Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,039,148 to 513,712, a change of -525,436 (-50.6%).
- Net loss of 2,323,705 reduced equity.
- New share issuances of 1,500,000 increased equity.
- Other factors increased equity by 298,269.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.32 Million | -452.34% |
| Share Issuances | $1.50 Million | +291.99% |
| Other Changes | $298.27K | +58.06% |
| Total Change | $- | -50.56% |
Book Value vs Market Value Analysis
This analysis compares Nuo Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 136.70x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 70.59x to 136.70x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.02 | $1.50 | x |
| 2018-12-31 | $0.00 | $1.50 | x |
| 2019-12-31 | $-0.02 | $1.50 | x |
| 2020-12-31 | $-0.01 | $1.50 | x |
| 2021-12-31 | $-0.01 | $1.50 | x |
| 2022-12-31 | $0.05 | $1.50 | x |
| 2023-12-31 | $0.02 | $1.50 | x |
| 2024-12-31 | $0.01 | $1.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nuo Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -452.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -170.21%
- • Asset Turnover: 1.15x
- • Equity Multiplier: 2.32x
- Recent ROE (-452.34%) is below the historical average (-358.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -122.08% | -243.28% | 0.14x | 3.64x | $-20.43 Million |
| 2015 | 0.00% | -458.76% | 1.63x | 0.00x | $-49.15 Million |
| 2016 | 180.03% | 1019.58% | 0.16x | 1.13x | $21.23 Million |
| 2017 | -3102.01% | -2077.36% | 0.51x | 2.95x | $-15.03 Million |
| 2018 | 0.00% | -112.49% | 1.41x | 0.00x | $-1.53 Million |
| 2019 | 0.00% | -817.43% | 0.93x | 0.00x | $-1.14 Million |
| 2020 | 0.00% | -1854.49% | 0.03x | 0.00x | $-39.29K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-38.42K |
| 2022 | -144.74% | -2825.60% | 0.04x | 1.39x | $-3.39 Million |
| 2023 | -305.20% | -521.17% | 0.32x | 1.81x | $-3.28 Million |
| 2024 | -452.34% | -170.21% | 1.15x | 2.32x | $-2.38 Million |
Industry Comparison
This section compares Nuo Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nuo Therapeutics Inc (AURX) | $-824.56K | -122.08% | N/A | $30.39 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |